PTIX Valuation

Protagenic Therapeutics Inc

Add to Watchlist

Advanced Chart

3.240

-0.13(-3.858%)1D

Overview
Forecast
Valuation
Earnings

PTIX Relative Valuation

PTIX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTIX is overvalued; if below, it's undervalued.

Historical Valuation

Protagenic Therapeutics Inc (PTIX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -3.70. The fair price of Protagenic Therapeutics Inc (PTIX) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：3.24

Fair

Trailing

Forward

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

-21.18

P/B

Median3y

0.70

Median5y

-0.62

-169.11

FCF Yield

Median3y

-90.84

Median5y

-64.16

Competitors Valuation Multiple

The average P/S ratio for PTIX's competitors is 0.04, providing a benchmark for relative valuation. Protagenic Therapeutics Inc Corp (PTIX) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

PTIX.O

Protagenic Therapeutics Inc

Loss

Average P/S: 0.04

2.81M